Analysts at Berenberg downgraded drugmaker GSK from 'buy' to 'hold' on Tuesday as it awaited upcoming product launches.

London: GSK plc has announced the New Drug Application (NDA) for linerixibat, an investigational targeted inhibitor of the ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the appointment of Chinmay Sharma, Executive Vice President - ...

US FDA accepts for review GSK’s NDA for linerixibat to treat cholestatic pruritus in patients with PBC: London, UK Tuesday, June 3, 2025, 11:00 Hrs [IST] GSK plc announced the U ...

This important study advances our understanding of population-level immune responses to influenza in both children and adults. The strength of the evidence supporting the conclusions is compelling, ...

Theravance Biopharma, Inc. has just announced the sale of its remaining royalty interest in Trelegy Ellipta to GSK for $225 ...

CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and ...

Andrew Witty, who largely led the U.S. healthcare giant from the U.K., made big bets on Medicare enrollees that backfired.

The GSK share price has had a horrible millennium. Harvey Jones can't believe how bad it's been. But are we starting to see ...

In a welcome move, GSK ADRGSK saw its Relative Strength Rating rise from 66 to 74 on Monday. Please watch the video at Investors.com - How To Find The Best IPO Stocks Can You Really Time The Stock ...

These mutated diseases defy the power of antibiotics. Are illnesses really mutating so fast that we can’t stay ahead of them?

With that, Theravance expects its lifetime value from the inhaler to come out to $1.52 billion. The drug stems from a 2002 ...